Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266666 | 1.00 | HCRTR2 (0.40) | HCRTR2CHEK1SSTR4SLC6A2SLC6A4 | |
| SCHEMBL12070332 | 1.00 | HCRTR2 (0.40) | HCRTR2CHEK1SSTR4SLC6A2SLC6A4 | |
| SCHEMBL22644684 | 0.91 | HCRTR2 (0.38) | HCRTR2EPHX1NPSR1MEN1KMT2A | |
| SCHEMBL22301022 | 0.86 | MEN1 (0.41) | HCRTR2SSTR4SLC6A2SLC6A4EPHX1 | |
| SCHEMBL13840040 | 0.86 | HCRTR2 (0.38) | HCRTR2EPHX1NPSR1TDP1MEN1 | |
| SCHEMBL16078153 | 0.85 | SLC6A2 (0.41) | CHEK1SLC6A2SLC6A4CHEK2ADRB2 | |
| SCHEMBL28025209 | 0.85 | SLC6A2 (0.41) | CHEK1SLC6A2SLC6A4CHEK2ADRB2 | |
| SCHEMBL28662054 | 0.82 | HCRTR2 (0.45) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| SCHEMBL28662052 | 0.82 | HCRTR2 (0.45) | HCRTR2EPHX1TDP1MEN1KMT2A | |
| SCHEMBL4185679 | 0.81 | CTSS (0.52) | NPSR1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4619097-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025105486-A1 | ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE | 第一三共株式会社 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106477-A1 | NOVEL AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | disclosed |
| US-5468742-A | Antibacterial agents, feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0671391-A1 | 5-Vinyl- and 5-ethinyl-quinolinone- and -naphthyridone-carboxylic acids | BAYER AG (DE) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0523512-A1 | 8-vinyl- and 8-ethinyl-quinolone carboxylic acids | BAYER AG (DE) | 1993-01-20 | — | — | EP | disclosed |
| EP-0468231-A2 | Guanidins | F. HOFFMANN-LA ROCHE AG (CH) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HCRTR2 4064/4885CHEK1 851/4885SSTR4 4498/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HCRTR2 4566/4885CHEK1 1559/4885SSTR4 4747/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | HCRTR2 4388/4885CHEK1 1095/4885SSTR4 3983/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | HCRTR2 4724/4885CHEK1 4328/4885SSTR4 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.